Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company)

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA)

MORRISVILLE, N.C. , Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today that Dr. Roger Jeffs , Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 , beginning at

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation Liquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C. , Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company)

MORRISVILLE, N.C. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million , before

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C. , Nov.

MORRISVILLE, N.C. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C. , Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S.

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVILLE, N.C. , Sept.

MORRISVILLE, N.C. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023 . The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate